Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats

被引:46
作者
Aravagiri, M [1 ]
Marder, SR [1 ]
机构
[1] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Psychopharmacol Unit, Los Angeles, CA 90073 USA
关键词
risperidone; 9-hydroxyrisperidone; pharmacokinetics; rat; oral dose; plasma; brain; tissue; LC-MS-MS;
D O I
10.1007/s00213-001-0933-x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Following an oral dose of risperidone (RSP), concentrations of its major metabolite 9-hydroxyrisperidone (9-OHRSP) were high in plasma and tissues but disproportionately lower in the brain compared to RSP, indicating that 9-OHRSP may have different pharmacokinetic properties. Objectives: To investigate non-compartmental pharmacokinetics of RSP and 9-OHRSP in plasma, brain and other tissues after separate administration of a single oral dose of 6 mg/kg RSP and 9-OHRSP to rats. Methods: Plasma, brain, liver, lung, kidney and spleen tissues were collected at pre-dose and at 0.5, 1, 2, 5, 6, 12, 24, 36 and 48 h post-dose, homogenized in saline and assayed for RSP and 9-OHRSP using a sensitive and specific liquid chromatography tandem mass spectrometry method. Results: The concentrationtime curve of RSP and 9-OHRSP showed that they were readily absorbed and followed a multiphase elimination pattern. The terminal elimination half-life (t(1/2)) of RSP after the RSP dose was longest in the liver (17.6 h) and shortest in the spleen (1.2 h). The t(1/2) of 9-OHRSP after the RSP dose was shorter in plasma (3.4 h) and other tissues (similar to8-11 h) than that for RSP but it was longer in the spleen. However, the t(1/2) of 9-OHRSP after the 9-OHRSP dose was shorter in most tissues as compared to the t(1/2) of 9-OHRSP after the RSP dose. The area under the concentration-time curve (AUC) of RSP and 9-OHRSP was 6-67 times higher in the plasma and tissues than in the brain. AUCs of 9-OHRSP in tissues after the RSP close were 2-5 times higher than those for RSP, except in the brain, where AUCs of RSP and 9-OHRSP were similar. Conclusion: Pharmacokinetics of 9-OHRSP in many tissues were different after RSP and 9-OHRSP doses. The reason for disproportionate brain levels of 9-OHRSP is not clear. The overall exposure to active drug in the brain as represented by AUC was similar after the RSP and 9-OHRSP doses and the 9-OHRSP is probably an equal contributor to the pharmacological actions of RSP.
引用
收藏
页码:424 / 431
页数:8
相关论文
共 23 条
[1]  
Aravagiri M, 2000, J MASS SPECTROM, V35, P718, DOI 10.1002/1096-9888(200006)35:6<718::AID-JMS999>3.0.CO
[2]  
2-O
[3]   Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: Simultaneous determination by a high performance liquid chromatography with electrochemical detection [J].
Aravagiri, M ;
Marder, SR ;
Wirshing, D ;
Wirshing, WC .
PHARMACOPSYCHIATRY, 1998, 31 (03) :102-109
[4]  
ARAVAGIRI M, 1995, NEUROPSYCHOPHARMACOL, V13, P235
[5]   Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy risperidone in the brain and other tissues of rat [J].
Aravagiri, M ;
Yuwiler, A ;
Marder, SR .
PSYCHOPHARMACOLOGY, 1998, 139 (04) :356-363
[6]   TISSUE CONCENTRATIONS OF CLOZAPINE AND ITS METABOLITES IN THE RAT [J].
BALDESSARINI, RJ ;
CENTORRINO, F ;
FLOOD, JG ;
VOLPICELLI, SA ;
HUSTONLYONS, D ;
COHEN, BM .
NEUROPSYCHOPHARMACOLOGY, 1993, 9 (02) :117-124
[7]  
BORISON RL, 1995, J CLIN PSYCHOPHAR S1, V15, P24
[8]  
CHOUINARD G, 1995, J CLIN PSYCHOPHAR S1, V15, P36
[9]   Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4 [J].
Fang, J ;
Bourin, M ;
Baker, GB .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (02) :147-151
[10]   POSITRON EMISSION TOMOGRAPHY STUDIES ON D-2 AND 5-HT2 RECEPTOR-BINDING IN RISPERIDONE-TREATED SCHIZOPHRENIC-PATIENTS [J].
FARDE, L ;
NYBERG, S ;
OXENSTIERNA, G ;
NAKASHIMA, Y ;
HALLDIN, C ;
ERICSSON, B .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1995, 15 (01) :S19-S23